This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Efficacy and Safety of BIIB019 (Daclizumab High Yi...
Clinical trial

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon ? 1a in Participants With Relapsing-Remitting Multiple Sclerosis (DECIDE)

Read time: 1 mins
Last updated:1st May 2010

The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis.

The secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis
Enrollment: 1841
Study Start Date: May 2010
Study Completion Date: July 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)

- Experimental:
Daclizumab High Yield Process 150 mg SC
- Active Comparator: IFN β-1a 30 µg IM

Category Value
Study start date 2010-05-01

View full details